In HD models, the administration of PPARγ agonists protects from striatal neurodegeneration, attenuates neuroinflammation and decreases oxidative damage [30–32], supporting PPARγ as a valid target for the management of HD. This evidence concerns the gene PPARG and Huntington disease.